IND clearance secured for Starlight Therapeutics and Myosin Therapeutics.

Pharma leaders Jazz Pharmaceuticals and Merck continue expanding into GBM through new investments and acquisitions.

Plus Therapeutics’ REYOBIQ shows a doubling of survival in recurrent GBM.

Denovo Biopharma’s DB102 advances into Phase III trials.

Starlight Therapeutics receives accelerated approval for its AI-enabled STAR-001 program.

Erik Fossel

CEO Viska Bio

Wednesday 18th February 2026

TALK 3: TARGETING GBM: NOVEL AGENT, UNIQUE MECHANISM